These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 9145209)
1. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209 [TBL] [Abstract][Full Text] [Related]
2. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Mori Y; Kitahara Y; Miura K; Tajima N Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195 [TBL] [Abstract][Full Text] [Related]
3. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Mine T; Miura K; Kitahara Y; Okano A; Kawamori R Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950 [TBL] [Abstract][Full Text] [Related]
4. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Ichikawa K; Yamato T; Ojima K; Tsuji A; Ishikawa K; Kusama H; Kojima M Clin Exp Pharmacol Physiol; 2002; 29(5-6):423-7. PubMed ID: 12010187 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats. Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228 [TBL] [Abstract][Full Text] [Related]
6. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Sato Y; Nishikawa M; Shinkai H; Sukegawa E Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797 [TBL] [Abstract][Full Text] [Related]
7. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089 [TBL] [Abstract][Full Text] [Related]
8. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858 [TBL] [Abstract][Full Text] [Related]
9. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes. Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197 [TBL] [Abstract][Full Text] [Related]
10. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Mori Y; Kitahara Y; Miura K; Mine T; Tajima N Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218 [TBL] [Abstract][Full Text] [Related]
11. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362 [TBL] [Abstract][Full Text] [Related]
12. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats. Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944 [TBL] [Abstract][Full Text] [Related]
13. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Mori Y; Ojima K; Fuujimori Y; Aoyagi I; Kusama H; Yamazaki Y; Kojima M; Shibata N; Itoh Y; Tajima N Endocrine; 2006 Apr; 29(2):309-15. PubMed ID: 16785606 [TBL] [Abstract][Full Text] [Related]
14. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs. Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes]. Ikenoue T; Kondo N Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747 [TBL] [Abstract][Full Text] [Related]
16. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment. Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725 [TBL] [Abstract][Full Text] [Related]
17. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide. Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834 [TBL] [Abstract][Full Text] [Related]